Fandom

Psychology Wiki

Genetic counseling: Medium-chain acyl-coenzyme A dehydrogenase Deficiency

34,203pages on
this wiki
Add New Page
Talk0 Share

Assessment | Biopsychology | Comparative | Cognitive | Developmental | Language | Individual differences | Personality | Philosophy | Social |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |

Clinical: Approaches · Group therapy · Techniques · Types of problem · Areas of specialism · Taxonomies · Therapeutic issues · Modes of delivery · Model translation project · Personal experiences ·



Medium-chain acyl-coenzyme A dehydrogenase Deficiency

OverviewEdit

  • Medium-chain acyl-coenzyme A dehydrogenase (MCAD) is an enzyme involved in mitochondrial fatty acid b-oxidation (FAO). Fatty acid oxidation provides energy for peripheral tissues when glycogen is depleted through hepatic ketogenesis. A defect in the MCAD enzyme causes accumulation of medium-chain fatty acids, metabolized to glycine- and carnitine-esters and dicarboxylic acids, and hypoketonia.

GeneticsEdit

  • MCAD deficiency is caused by a mutation in the ACADM gene
  • Chromosomal locus 1p31
  • 31 known disease causing mutations
  • 1 common mutation, K304E, accounts for 76% of alleles

IncidenceEdit

  • Common in Caucasians, especially with Northern European ancestry
  • Disease incidence 1:4,900 to 1:17,000
  • Carrier frequency 1:40 to 1:100
  • Less common among Hispanics
  • Rare in African-American, and Native-American populations

DiagnosisEdit

  • Metabolic testing
  • Symptomatic individuals should have plasma acylcarnitines, plasma fatty acids, urine organic acids, and urine acylclycines analyzed and interpreted.
  • Enzymatic testing
  • MCAD enzyme activity should be measured in fibroblasts or other tissues to confirm diagnosis
  • Molecular testing
  • Molecular genetic testing by mutation analysis (for K204E) or sequence analysis of the ACADM gene can confirm diagnosis
  • Newborn screening
  • MCAD is part of the newborn screening panel in 9 states (IA, ME, MA, NC, OH, SC, SD, WI, WY).
  • Prenatal testing
  • Enzymatic or molecular testing can be performed prenatally; however, there is limited benefit to prenatal vs. newborn testing.
  • Carrier testing
  • Only molecular testing can determine carrier status.

Clinical FeaturesEdit

  • Typical presentation includes hypoketotic hypoglycemia, vomiting, lethargy,

seizures, and coma precipitated by prolonged fasting or common illness.

  • Hepatomegaly and acute liver disease may also be present.
  • Sudden, unexplained death may be first symptom (18%).

Natural HistoryEdit

  • Typically normal at birth following uneventful pregnancy
  • Most present with symptoms between 3 and 24 months in response to prolonged fasting or infection
  • Initial presentation in adulthood also possible
  • Affected individuals may lose developmental milestones or acquire aphasia or ADD as a result of acute metabolic event
  • Individuals identified as newborns typically develop normally under treatment

InheritanceEdit

  • MCAD deficiency is an autosomal recessive disorder.

TestingEdit

  • Enzymatic and Molecular testing can confirm diagnosis.
  • Both mutation and sequence analysis are available on a clinical basis.

Management & TreatmentEdit

  • MCAD is a highly treatable condition- good prognosis when managed
  • Avoidance of fasting is key-
  • Infants should be fed frequently
  • Toddlers should be given 2 g/kg uncooked cornstarch before bed
  • Low-fat diet and carnitine supplementation may be beneficial

Differential DiagnosisEdit

  • Other disorders of acyl-CoA dehydrogenase (ACAD) gene family
  • Other disorders of fatty acid b-oxidation

Psychosocial IssuesEdit

  • Parental guilt over allowing too long of time between feedings which triggered onset of symptoms
  • Parental guilt over passing gene to child
  • When presenting symptom is sudden death, loss of seemingly healthy child can be devastating
  • Parent or sibling may be identified as a homozygote during carrier testing
  • Family planning- risk for future offspring/siblings of affected individual

Patient ResourcesEdit

  • FOD (Fatty Oxidation Disorder) Family Support Group
805 Montrose Drive
Greensboro, NC 27410
Phone: (336) 547-8682
Email: deb@fodsupport.org
Web: www.fodsupport.org
  • Organic Acidemia Association
13210 35th Avenue North
Plymouth, MN 55441
Phone; (763) 556-1797
Email: OAANews@aol.com
Web: www.oaanews.org
  • United Mitochondrial Disease Foundation
8085 Saltsburg Road, Suite 201
Pittsburgh, PA 15239
Phone: (412) 793-8077
Email: info@umdf.org
Web: www.umdf.org

NotesEdit

The informaiton in this outline was last updated in Feb 2003.


This material has been imported fom the wikibook "Genetic counseling"[ http://en.wikibooks.org/wiki/Genetic_counseling] under the GNU Free Documentation License.

Heckert GNU white Permission is granted to copy, distribute and/or modify this document under the terms of the GNU Free Documentation License, Version 1.2 or any later version published by the Free Software Foundation; with no Invariant Sections, no Front-Cover Texts, and no Back-Cover Texts. A copy of the license is included in the section entitled "GNU Free Documentation License."

Ad blocker interference detected!


Wikia is a free-to-use site that makes money from advertising. We have a modified experience for viewers using ad blockers

Wikia is not accessible if you’ve made further modifications. Remove the custom ad blocker rule(s) and the page will load as expected.

Also on Fandom

Random Wiki